Is TKI therapy effective in patients with ABL-class fusion ALL?

During the 25th Congress of the European Hematology Association (EHA), the ALL Hub spoke to Anthony Moorman, Newcastle University, Newcastle upon Tyne, UK. We asked, Is TKI therapy effective in patients with ABL-class fusion ALL?

ABL-class fusions refer to a group of gene fusions that are observed in a small proportion of child patients with ALL, and fall under the group of BCR-ABL/Philadelphia-like ALL. These patients are associated with higher instances of relapse; efforts are underway to improve patient outcomes in this setting. This interview focuses on patients with ABL-class fusion ALL who were treated on the UKALL 2011 trial.